Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/22/22 Merck (MRK) Keytruda for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
11/17/22 Astellas Pharma (4503:JP) Zolbetuximab for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
11/16/22 Mineralys MLS-101 for Hypertension (Systemic) Subscribers Only Subscribers Only Subscribers Only
11/16/22 Ardelyx (ARDX) XPHOZAH for Hyperphosphatemia Subscribers Only Subscribers Only Subscribers Only
11/15/22 Arcutis (ARQT) Zoryve for Atopic Dermatitis (Eczema) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
11/29/22 Subscribers Only Subscribers Only Trial Data - Updated Results
Now - 11/30/22 Subscribers Only Subscribers Only Regulatory - CHMP (European Panel) Results
Now - 11/30/22 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Japan)
Now - 11/30/22 Subscribers Only Subscribers Only Trial Announcement - Initiation
Now - 11/30/22 Subscribers Only Subscribers Only Trial Announcement - Initiation (Emerging Markets)
Back to the top Back to the top